Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carboplatin + Etoposide |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| Etoposide | Vepesid | EPEG|Eposin|VP-16|VP-16-213 | TOPO2 inhibitor 5 | Vepesid (etoposide) binds to and inhibits DNA topoisomerase II, resulting in accumulated DNA damage, inhibition of replication, and cell death (NCI Drug Dictionary). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02130869 | Phase I | Bendamustine + Cytarabine + Etoposide Busulfan + Hu14.18K322A Aldesleukin + Melphalan + Sargramostim Filgrastim Carboplatin + Etoposide | A Pilot Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+ Positively-Selected Autologous Hematopoietic Stem Cells in Children With High Risk Solid Tumors or Lymphomas | Completed | USA | 0 |
| NCT03382561 | Phase II | Cisplatin + Etoposide + Nivolumab Carboplatin + Etoposide + Nivolumab Cisplatin + Etoposide Carboplatin + Etoposide | Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Lung Cancer | Active, not recruiting | USA | 0 |
| NCT02748889 | Phase Ib/II | Carboplatin + Etoposide Atezolizumab + Carboplatin + Etoposide | Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer | Terminated | USA | 0 |
| NCT03811002 | Phase II | Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide | Chemoradiation With or Without Atezolizumab in Treating Patients With Limited Stage Small Cell Lung Cancer | Active, not recruiting | USA | 1 |
| NCT02499770 | Phase Ib/II | Carboplatin + Etoposide Trilaciclib | G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) | Completed | USA | POL | HUN | FRA | ESP | 2 |
| NCT02763579 | Phase III | Atezolizumab + Carboplatin + Etoposide Carboplatin + Etoposide | A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer (IMpower133) | Completed | USA | POL | ITA | HUN | GRC | GBR | FRA | ESP | DEU | CZE | BRA | AUT | AUS | 8 |
| NCT05572476 | Phase II | Durvalumab + Lurbinectedin Carboplatin + Etoposide | Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer (LURBIMUNE) | Withdrawn | FRA | 0 |
| NCT03017326 | Phase III | Cisplatin Carboplatin + Etoposide Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Carboplatin + Doxorubicin Irinotecan + Vincristine Sulfate Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin | Paediatric Hepatic International Tumour Trial (PHITT) | Active, not recruiting | POL | NOR | NLD | ISR | IRL | GBR | FRA | FIN | ESP | DEU | CZE | CHE | BEL | AUT | 0 |
| NCT05566041 | Phase III | Cisplatin + Etoposide Carboplatin + Etoposide + RRx-001 Cisplatin + Etoposide + RRx-001 Carboplatin + Etoposide | A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer (REPLATINUM) | Active, not recruiting | USA | 0 |
| NCT05058651 | Phase II | Atezolizumab + Carboplatin + Etoposide Atezolizumab + Cisplatin + Etoposide Cisplatin + Etoposide Carboplatin + Etoposide | Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Metastatic Small Cell Neuroendocrine Carcinomas That Originate Outside the Lung | Recruiting | USA | 0 |
| NCT02017964 | Phase II | Carboplatin + Etoposide Cyclophosphamide + Methotrexate + Vincristine Sulfate | Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-Metastatic Desmoplastic Medulloblastoma | Completed | USA | CAN | AUS | 1 |
| NCT03066778 | Phase III | Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide | A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604) | Completed | USA | TUR | POL | NZL | ISR | IRL | HUN | GBR | FRA | ESP | DEU | CHE | CAN | AUS | 5 |
| NCT04624204 | Phase III | Pembrolizumab Cisplatin + Etoposide Cisplatin + Etoposide + Pembrolizumab Carboplatin + Etoposide Olaparib + Pembrolizumab Carboplatin + Etoposide + Pembrolizumab | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013) | Active, not recruiting | USA | TUR | ROU | LTU | ITA | ISR | HUN | GRC | GBR | FRA | EST | ESP | CAN | BGR | BEL | AUS | 9 |
| NCT01722292 | Phase Ib/II | Taladegib Carboplatin + Etoposide | A Study of LY2940680 in Small Cell Lung Cancer | Terminated | USA | GBR | 0 |
| NCT06333314 | Phase II | Dostarlimab-gxly Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin Doxorubicin Gemcitabine Gemcitabine + Nab-paclitaxel Doxorubicin + Trabectedin Fluorouracil + Leucovorin + Oxaliplatin Cisplatin + Etoposide Cisplatin + Gemcitabine Cisplatin + Doxorubicin + Etoposide Capecitabine + Oxaliplatin Doxorubicin + Ifosfamide Carboplatin + Etoposide Carboplatin + Paclitaxel Docetaxel + Fluorouracil + Leucovorin + Oxaliplatin Mitotane | Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI (Pan-MSI-ACSE) | Recruiting | FRA | 0 |
CKB BOOST